COSCIENS Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . COSCIENS Biopharma
CSCI Stock   2.68  0.03  1.11%   
COSCIENS Biopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing COSCIENS Biopharma's valuation are provided below:
Gross Profit
4.4 M
Profit Margin
(2.00)
Market Capitalization
8.6 M
Enterprise Value Revenue
0.1389
Revenue
9.4 M
We have found one hundred twenty available fundamental signals for COSCIENS Biopharma, which can be analyzed and compared to other ratios and to its rivals. Traders should compare all of COSCIENS Biopharma prevailing fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 7.8 M. The COSCIENS Biopharma's current Enterprise Value is estimated to increase to about (6.5 M)

COSCIENS Biopharma Total Revenue

16.64 Million

Check COSCIENS Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among COSCIENS Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.9 M, Interest Expense of 99.3 K or Total Revenue of 16.6 M, as well as many indicators such as Price To Sales Ratio of 0.57, Dividend Yield of 0.0 or PTB Ratio of 0.59. COSCIENS financial statements analysis is a perfect complement when working with COSCIENS Biopharma Valuation or Volatility modules.
  
Build AI portfolio with COSCIENS Stock
Check out the analysis of COSCIENS Biopharma Correlation against competitors.
For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.

COSCIENS Biopharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets42.3 M40.3 M20.1 M
Slightly volatile
Short and Long Term Debt Total1.7 M2.7 M2.2 M
Slightly volatile
Other Current Liabilities5.2 M4.9 M1.7 M
Slightly volatile
Total Current Liabilities8.7 M8.3 M4.2 M
Slightly volatile
Total Stockholder Equity15.9 M15.1 M12.5 M
Slightly volatile
Property Plant And Equipment Net13.2 M12.6 M8.8 M
Slightly volatile
Accounts Payable2.9 M2.8 M1 M
Slightly volatile
Cash19.8 M18.9 M6 M
Slightly volatile
Non Current Assets Total13.5 M10 M10.4 M
Slightly volatile
Cash And Short Term Investments19.8 M18.9 M6 M
Slightly volatile
Net Receivables3 M2.8 M1.4 M
Slightly volatile
Common Stock Shares Outstanding3.1 M3 M1.8 M
Slightly volatile
Liabilities And Stockholders Equity42.3 M40.3 M20.1 M
Slightly volatile
Non Current Liabilities Total17.7 M16.9 M7.3 M
Slightly volatile
Inventory3.2 M3.1 M1.4 M
Slightly volatile
Other Stockholder Equity7.1 M3.8 M5.4 M
Slightly volatile
Total Liabilities26.5 M25.2 M7.6 M
Slightly volatile
Total Current Assets29 M27.6 M9.6 M
Slightly volatile
Short Term Debt350.6 K243.9 K602.8 K
Slightly volatile
Intangible Assets6 K6.3 K283.2 K
Slightly volatile
Current Deferred Revenue131.1 K138 K907.7 K
Pretty Stable
Common Stock14.3 M25.9 M13.3 M
Slightly volatile
Good Will139.1 K156.5 K170.8 K
Slightly volatile
Long Term Debt37.7 K42.4 K46.3 K
Slightly volatile
Short and Long Term Debt85.5 K65 K113.3 K
Slightly volatile
Capital Lease Obligations2 M2.1 M2.7 M
Slightly volatile
Net Invested Capital20.1 M11.8 M23.6 M
Slightly volatile
Property Plant And Equipment Gross20.8 M18.1 M25.5 M
Slightly volatile
Capital Stock19.6 M25.9 M17.6 M
Slightly volatile
Net Working Capital14.8 M19.3 M10.5 M
Slightly volatile

COSCIENS Biopharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.9 M1.8 M808.7 K
Slightly volatile
Interest Expense99.3 K148.3 K101.2 K
Slightly volatile
Total Revenue16.6 M15.9 M9.7 M
Slightly volatile
Gross Profit8.2 M7.8 M5.2 M
Slightly volatile
Other Operating Expenses48.4 M46.1 M14.1 M
Slightly volatile
Research Development4.9 M9.5 M2.4 M
Slightly volatile
Cost Of Revenue8.4 M8 M4.5 M
Slightly volatile
Total Operating Expenses39.9 M38 M9.6 M
Slightly volatile
Selling General Administrative12.6 M12 M3.9 M
Slightly volatile
Selling And Marketing Expenses26.1 K27.5 K88.4 K
Slightly volatile
Reconciled Depreciation1.6 M1.8 M1.5 M
Slightly volatile
Interest Income532.5 K507.1 K201.5 K
Slightly volatile

COSCIENS Biopharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow8.1 M7.7 M3.7 M
Slightly volatile
Depreciation1.9 M1.8 M831.9 K
Slightly volatile
Capital Expenditures1.1 M1 M1.6 M
Slightly volatile
Stock Based Compensation560.3 K533.6 K216.8 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.570.630.8 K
Slightly volatile
Days Sales Outstanding58.175.2546.8264
Slightly volatile
Book Value Per Share3.624.597.6861
Pretty Stable
Average Payables1.6 M1.4 M1.3 M
Slightly volatile
Stock Based Compensation To Revenue0.03180.03030.0217
Pretty Stable
Capex To Depreciation0.790.835.4475
Slightly volatile
Inventory Turnover2.842.984.443
Pretty Stable
Days Of Inventory On Hand123162153
Pretty Stable
Payables Turnover2.292.613.8922
Pretty Stable
Sales General And Administrative To Revenue0.720.680.3649
Slightly volatile
Average Inventory2.2 M2.1 M1.1 M
Slightly volatile
Research And Ddevelopement To Revenue0.880.690.25
Slightly volatile
Capex To Revenue0.0920.09690.7549
Slightly volatile
Cash Per Share7.127.34.0261
Pretty Stable
Days Payables Outstanding137145169
Slightly volatile
Intangibles To Total Assets3.0E-43.0E-40.2036
Slightly volatile
Current Ratio3.272.992.8028
Slightly volatile
Receivables Turnover6.096.419.8493
Pretty Stable
Capex Per Share0.490.521.3836
Slightly volatile
Average Receivables1.1 M1.1 M938.3 K
Slightly volatile
Revenue Per Share5.164.815.1193
Slightly volatile
Interest Debt Per Share1.871.542.0868
Slightly volatile
Debt To Assets0.10.110.1824
Slightly volatile
Graham Number31.4929.9918.1701
Slightly volatile
Operating Cycle194237242
Slightly volatile
Days Of Payables Outstanding137145169
Slightly volatile
Quick Ratio3.02.652.2964
Slightly volatile
Cash Ratio1.422.041.6211
Slightly volatile
Days Of Inventory Outstanding123162153
Pretty Stable
Days Of Sales Outstanding58.175.2546.8264
Slightly volatile
Fixed Asset Turnover1.071.1319.5565
Very volatile
Debt Ratio0.10.110.1824
Slightly volatile
Price Sales Ratio0.570.630.8 K
Slightly volatile
Asset Turnover0.430.450.6192
Slightly volatile
Gross Profit Margin0.370.440.4991
Very volatile

COSCIENS Biopharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap7.8 M8.2 M24 B
Slightly volatile

COSCIENS Fundamental Market Drivers

About COSCIENS Biopharma Financial Statements

Investors use fundamental indicators, such as COSCIENS Biopharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although COSCIENS Biopharma's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue138 K131.1 K
Total Revenue15.9 M16.6 M
Cost Of Revenue8 M8.4 M
Stock Based Compensation To Revenue 0.03  0.03 
Sales General And Administrative To Revenue 0.68  0.72 
Research And Ddevelopement To Revenue 0.69  0.88 
Capex To Revenue 0.10  0.09 
Revenue Per Share 4.81  5.16 
Ebit Per Revenue(1.72)(1.63)

Currently Active Assets on Macroaxis

FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
CSANCosan SA ADR
RKTRocket Companies
When determining whether COSCIENS Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of COSCIENS Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cosciens Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cosciens Biopharma Stock:
How To Invest In COSCIENS
Details
Is COSCIENS Stock a good investment?
Details
What is COSCIENS Biopharma's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of COSCIENS Biopharma Correlation against competitors.
For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is there potential for Biotechnology market expansion? Will COSCIENS introduce new products? Factors like these will boost the valuation of COSCIENS Biopharma. Projected growth potential of COSCIENS fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about COSCIENS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.54)
Revenue Per Share
2.996
Quarterly Revenue Growth
0.176
Return On Assets
(0.17)
Return On Equity
(1.13)
Understanding COSCIENS Biopharma requires distinguishing between market price and book value, where the latter reflects COSCIENS's accounting equity. The concept of intrinsic value - what COSCIENS Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push COSCIENS Biopharma's price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
It's important to distinguish between COSCIENS Biopharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding COSCIENS Biopharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, COSCIENS Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY